Parallel Bio
Corporate Program Manager, Firmwide
New York, NY, Remote. Posted a month ago
The role
The Corporate Program Manager will steward the company's highest-priority initiatives and strategic programs. This person will translate strategy into execution by managing roadmaps, OKRs, and planning artifacts across various functions.
What you will do
- Steward the company's highest-priority initiatives from definition through to delivery.
- Support the Executive Team on critical initiatives and strategic opportunities.
- Coordinate cross-functional initiatives spanning Science, Platform, Technology and the Executive Team.
- Work with Finance and Operations to ensure resourcing and timelines reflect budget and constraints.
- Surface risks, remove obstacles, and resolve dependencies.
- Steward company and function roadmaps and maintain canonical versions of artifacts.
- Develop and calibrate content for executive communications and strategic narratives.
- Centralize decisions, documentation, and updates in Notion and the project management tool.
- Drive the effectiveness of the Leadership Team through operating rhythms and decision frameworks.
- Own the migration of projects, issues and history onto a single designated project management system.
Required qualifications
- 5+ years supporting senior leadership or operations
- At least two startups or high-growth teams in biotech, deep tech, or science-driven environments
- Experience stewarding high-stakes programs as the single accountable person
- Experience running programs across time zones
- Experience consolidating teams onto a single project management system
- Deep working knowledge of modern issue tracking and project management systems
- Knowledge of Notion for documentation and dashboards
- Knowledge of Slack for automation and integrations
- Use of automation and language models
- Ability to break large goals into trackable milestones
- Ability to write and speak with influence
- Comfortable with ambiguity
About the company
parallel-bio is building a human-first drug discovery platform powered by organoids and AI. The company has raised approximately $30M from investors including AIX Ventures, Marc Benioff, Jeff Dean, and Y Combinator.